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To investigate the association between longitudinal changes in proton magnetic resonance
spectroscopy (MRS) metabolites and amyloid pathology in individuals without dementia, and
to explore the relationship between MRS and cognitive decline.
Methods
In this longitudinal multiple time point study (a subset of the Swedish BioFINDER), we
included cognitively healthy participants, individuals with subjective cognitive decline, and
individuals with mild cognitive impairment. MRS was acquired serially in 294 participants (670
individual spectra) from the posterior cingulate/precuneus. Using mixed-eﬀects models, we
assessed the association betweenMRS and baseline β-amyloid (Aβ), and betweenMRS and the
longitudinal Mini-Mental State Examination, accounting for APOE, age, and sex.
Results
While baseline MRS metabolites were similar in Aβ positive (Aβ+) and negative (Aβ−) indi-
viduals, in the Aβ+ group, the estimated rate of change was +1.9%/y for myo-inositol (mI)/
creatine (Cr) and −2.0%/y for N-acetylaspartate (NAA)/mI. In the Aβ− group, mI/Cr and
NAA/mI yearly change was −0.05% and +1.2%; however, this was not signiﬁcant across time
points. The mild cognitive impairment Aβ+ group showed the steepest MRS changes, with an
estimated rate of +2.93%/y (p = 0.07) for mI/Cr and −3.55%/y (p < 0.01) for NAA/mI.
Furthermore, in the entire cohort, we found that Aβ+ individuals with low baseline NAA/mI had
a signiﬁcantly higher rate of cognitive decline than Aβ+ individuals with high baseline NAA/mI.
Conclusion
We demonstrate that the longitudinal change in mI/Cr and NAA/mI is associated with un-
derlying amyloid pathology. MRS may be a useful noninvasive marker of Aβ-related processes
over time. In addition, we show that in Aβ+ individuals, baseline NAA/mI may predict the rate
of future cognitive decline.
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Accumulation of β-amyloid (Aβ) in the brain is the main hall-
mark of Alzheimer disease (AD), and can be detected by ana-
lyzing CSF Aβ42 levels. In AD, CSF Aβ42 might change before
Aβ ﬁbrils become detectable with PET,1 and is the earliest
disease biomarker to become abnormal.2 Magnetic resonance
spectroscopy (MRS) is a noninvasive technique that allows
quantiﬁcations of speciﬁc brain metabolites in vivo.
Recent MRS studies provide evidence of myo-inositol (mI)
being the most relevant MRSmetabolite in AD.3–5 Speciﬁcally,
elevated mI seems to be related to Aβ plaque pathology—
higher baseline levels of mI are associated with increased
Aβ accumulation over time.5 Another MRS metabolite
consistently changed in dementia is the neuronal markerN-
acetylaspartate (NAA).
In this study, we investigate the association between longi-
tudinal changes in the ratios mI/creatine (Cr) and NAA/mI
and amyloid pathology. MRS measurements from a single
voxel located in the posterior cingulate cortex (PCC)/
precuneus were acquired serially from 294 participants at
baseline and 2- and 4-year follow-up. Using information on
the presence of amyloid pathology and the genetic risk factor
APOE e4, we aimed to investigate the extent to which the rates
of change in MRS metabolites mI/Cr and NAA/mI are asso-
ciated with Aβ pathology. Furthermore, we explored whether
baseline levels of NAA/mI were able to predict future cognitive
decline.
Methods
Standard protocol approvals, registrations,
and patient consents
All participants gave written consent to participate in the
study. Ethical approval was given by the ethical committee of
Lund University, Sweden.
Participants
This study only contained data from individuals without de-
mentia (characterized as cognitively normal [CTL]), indi-
viduals with subjective cognitive decline (SCD), or those with
mild cognitive impairment (MCI). The participants stemmed
from the Swedish BioFINDER (Biomarkers for Identifying
Neurodegenerative Disorders Early and Reliably) Study (de-
tailed information available at bioﬁnder.se).
The CTL subset included participants based on the fol-
lowing characteristics: (1) baseline age 60 years or older,
(2) 28–30 Mini-Mental State Examination (MMSE) points
at the time of the screening, (3) no subjective cognitive im-
pairment, and (4) ﬂuent Swedish. Participants were excluded if
there was evidence of signiﬁcant neurologic or psychiatric
disease, MCI, or dementia.
Participants with SCD and MCI were enrolled from 3
outpatient memory clinics. Individuals were eligible if they:
(1) were referred to the memory clinic because of cognitive
impairment, (2) did not fulﬁll the criteria for any dementia
disorder, (3) had an MMSE of 24–30 points at the time of
screening, (4) were 60 to 80 years old, and (5) were ﬂuent
in Swedish. Participants were excluded if (1) the cause
of their cognitive impairment was clearly other than pro-
dromal dementia, (2) they had signiﬁcant somatic disease,
or (3) they refused to undergo neuropsychological as-
sessment or lumbar puncture. The classiﬁcation into SCD
and MCI was based on a comprehensive battery of neu-
ropsychological tests as well as an evaluation by a senior
neuropsychologist.
In the current study, only participants with baseline CSF and
high-quality MRS data were eligible. A total of 294 partic-
ipants were investigated: healthy controls (n = 137) from co-
hort 1, and patients with SCD (n = 83) and patients with MCI
(n = 74) from cohort 2.
MRS acquisition and analysis
MRS was performed on a 3-tesla Siemens TrioTim scanner
(Siemens Medical Solutions, Malvern, PA), using the point-
resolved spectroscopy single-voxel sequence, at an echo
time of 30 milliseconds (ms) and a repetition time of 2,000
ms. The 2 × 2 × 2 cm3 voxel was situated in the midsagittal
PCC/precuneus region. This area has been recommended
as the appropriate region for MRS in AD,6 and has fre-
quently been the region of choice by previous large-scale
MRS studies.5,7,8 Metabolite levels were quantiﬁed relative
total creatine (creatine + phosphocreatine, Cr) concen-
tration, due to the relative stability of the resonance peak of
Cr.9 Another marker routinely examined using MRS is
choline (Cho). Although the signiﬁcance of Cho changes
for AD pathology is unclear, we present these data brieﬂy in
the report.
MRS spectra were processed using the LCmodel10,11 soft-
ware and inspected for artifacts and quality. A total of 214
individual spectra were excluded from the analysis. In-
dividual spectra were excluded because of insuﬃcient
Glossary
Aβ = β-amyloid; AD = Alzheimer disease; BioFINDER = Biomarkers for Identifying Neurodegenerative Disorders Early and
Reliably; Cho = choline; Cr = creatine; CTL = cognitively normal control; MCI = mild cognitive impairment; mI = myo-
inositol;MMSE =Mini-Mental State Examination;MRS =magnetic resonance spectroscopy;NAA =N-acetylaspartate; PCC =
posterior cingulate cortex; SCD = subjective cognitive decline.
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quality; individuals were excluded when no baseline spec-
trum was available, as well as when spectra from only one
time point existed (ﬂowchart data available from Dryad,
Additional Methods, doi.org/10.5061/dryad.rd681sp). The
mean FWHM (full width at half maximum) of the remaining
spectra was 6.6 Hz (SD = 1.6 Hz); mean signal-to-noise ratio
was 24 (SD = 4.5). LCModel uses estimated SDs (Crame´r-
Rao lower bounds) as reliability indicators for metabolite
concentrations; the value of %SD <20% is often used as
a limit for acceptable reliability. However, metabolites mI,
NAA, and Cho are readily detectable at echo time = 30 ms;
for mI/Cr, NAA/Cr, and Cho/Cr, %SD was ≤7% for all
spectra.
CSF acquisition and analysis
The procedure of CSF collection and analysis followed the
Alzheimer’s Association ﬂowchart for CSF biomarkers.12,13
Lumbar CSF samples were collected at 3 centers, stored in
polypropylene tubes at −80°C and analyzed at the same time
using 2 ELISAs. CSF Aβ42 was analyzed by INNOTEST
ELISAs (Fujirebio Europe, Ghent, Belgium).14 CSF Aβ42 con-
centration ≤530 ng/L was considered abnormal, as previously
published.4
Statistical procedures
Cross-sectional between-group diﬀerences in MRS data were
assessed using analysis of variance, accounting for age, sex, and
APOE e4 carriership, and Tukey honestly signiﬁcant diﬀer-
ence test for post hoc analyses.
Longitudinal mI/Cr and NAA/mI changes were analyzed
using linear mixed-eﬀects models with subject-speciﬁc
intercepts. Fixed eﬀects were selected depending on the
primary research question. In model 1, the ﬁxed eﬀects
were baseline CSF Aβ group (normal/abnormal), visit
number, and the Aβ group-by-visit interaction. In model 2,
the ﬁxed eﬀects were baseline clinical diagnosis, visit num-
ber, and the diagnosis-by-visit interaction. Models 1 and
2 were created using data from all participants. Model 3
was analogous to model 1, while only using data from
patients with MCI. Models 1–3 took into account baseline
age, sex, and APOE e4 carriership. Annualized percentual
changes in MRS measures were derived from the model
estimates by taking the average of the estimated rates of
metabolite concentration change between visits 1 and 2, and
visits 1 and 3. The interaction term APOE × visit was not
included in the ﬁnal models, since it was found to be in-
signiﬁcant in all models for both outcome variables mI/Cr
and NAA/mI.
A similar approach was used in the analysis of longitudinal
cognitive data. Here, we modeled the change in MMSE score
over time as a function of baseline NAA/mI values. The ﬁxed
eﬀects were baseline NAA/mI (high/low), visit number, and
the NAA/mI-by-visit interaction. When modeling cognitive
decline over time, we took into account age, sex, years of
education, and APOE e4 status.
Since the APOE e2 allele may have a neuroprotective eﬀect of
the e2 allele, 8 participants with genotype e2/e4 were ex-
cluded from the analyses.
Statistical analyses were performed using R (R Foundation for
Statistical Computing, Vienna, Austria, r-project.org).
Data availability
Anonymized data will be shared by request from any qualiﬁed
investigator for the sole purpose of replicating procedures and
results presented in the report provided that data transfer is in




A total of 670 individual spectra were acquired, averaging ap-
proximately 2.2 spectra per individual for CTL, 2.4 for SCD,
and 2.3 for MCI. The timing and number of spectra are pre-
sented in table 1. Demographic details of the diagnostic groups
are presented in table 2. As expected, there were diﬀerences in
cognitive function across the 3 diagnostic groups both at
baseline and follow-up (table 2). Voxel placement and an ex-
ample of serially acquired spectra are presented in ﬁgure 1, A
and B.







Sex, M/F 57/80 36/47 41/33
Age, y 72.8 (4.7) 70.2 (5.5) 69.9 (4.9)






Education, y 12.3 (3.6) 13.1 (3.6)a 11.6 (3.4)a,b
MMSE score
Baselinec 29.0 (1.0) 28.5 (1.5) 27.5 (1.8)
2-y follow-upd 28.9 (1.7) 28.4 (2.7) 25.3 (3.5)
4-y follow-upe,f 28.6 (1.7) 27.3 (4.3) 23.5 (3.9)
Abbreviations: Aβ42 = β-amyloid 1–42; CTL = cognitively normal control;
MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination;
SCD = subjective cognitive decline.
Values are reported as mean (SD).
a There was a significant difference in the years of education between the
SCD and the MCI groups (p = 0.04).
b Education data were missing for 1 patient with MCI.
c BaselineMMSE data significantly different between all diagnostic groups (p
< 0.01).
d MMSE 2-year follow-up scores were significantly different between CTL
and MCI groups (p < 0.001).
e MMSE 4-year follow-up scores were significantly different between all
groups (p < 0.05).
f At 4-year follow-up,MMSE data weremissing for 47 CTL, 26 individuals with
SCD, and 24 with MCI.
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Cross-sectional MRS
MRS values at baseline, visit 2, and visit 3, and cross-sectional
comparisons across diagnostic groups are presented in ﬁgure 1,
C and D, and data available from Dryad (Additional Results,
doi.org/10.5061/dryad.rd681sp). At baseline, none of the
metabolite ratios diﬀered between diagnostic groups. On visit
2, MCI displayed higher mI/Cr and Cho/Cr values and lower
NAA/mI and NAA/Cr than CTL and SCD (p < 0.05). On
visit 3, NAA/mI remained signiﬁcantly lower in MCI than
CTL and SCD (p < 0.05), whereas mI/Cr remained higher
for MCI compared to CTL (p < 0.05) and NAA/Cr remained
lower for MCI compared to SCD (p < 0.05).
When we compared groups based on the individuals’ Aβ
status, we found no diﬀerences at baseline. At visits 2 and 3,
the diﬀerences in mI/Cr, NAA/Cr, and NAA/mI were sig-
niﬁcant between Aβ-positive and -negative cases (p < 0.05).
MRS values and cross-sectional comparisons across groups
based on Aβ status are shown in data available from Dryad
(Additional Results, doi.org/10.5061/dryad.rd681sp).
Longitudinal MRS
The rate of change of MRS measures mI/Cr and NAA/mI
was estimated using mixed-eﬀect models (table 3).
Model 1 was created using data from the entire cohort, in order
to assess whether baseline Aβ status aﬀects the rate of change in
mI/Cr and NAA/mI, accounting for baseline age, sex, and
APOE e4 carriership. Thus, the primary parameter of interest
for model 1 was the interaction between Aβ status and visit
number. We found that although higher Aβ was not associated
with higher mI/Cr levels at baseline, the estimates of longitu-
dinal change inmI/Cr andNAA/mIwere signiﬁcantly diﬀerent




participants CTL SCD MCI
Visit 1 0 294 137 83 74
Visit 2 2.28 (0.38) 294 137 83 74
Visit 3 4.10 (0.19) 82 24 34 24
Abbreviations: CTL = cognitively normal control; MCI = mild cognitive im-
pairment; SCD = subjective cognitive decline.
Figure 1 Voxel placement, serial MRS acquisition, and metabolite levels across diagnoses and biomarker groups
(A) Example of an MRS voxel placement and (B) acquired serial spectra at baseline, visit 1, and visit 2, from a 73-year-old cognitively healthy woman. (C–F)
Serial spectroscopic data across diagnostic groups. (C) mI/Cr ratio levels, (D) NAA/Cr ratio levels, (E) NAA/mI ratio levels, (F) Cho/Cr ratio levels. Significant
between-group differences (reported at *p < 0.05) were obtained using analysis of variance, accounting for age, sex and APOE e4 carriership, with Tukey
honestly significant difference tests for post hoc comparisons. Aβ+ = CSF Aβ42 ≤530 ng/L; Aβ− = CSF Aβ42 >530 ng/L. Aβ = β-amyloid; Cho = choline; Cr =
creatine; CTL = cognitively normal control; MCI = mild cognitive impairment; mI = myo-inositol; MRS = magnetic resonance spectroscopy; NAA = N-acety-
laspartate; SCD = subjective cognitive decline.
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Table 3 Specifications of the mixed models estimating the rate of change of MRS measures mI/Cr and NAA/mI
Fixed effects
Outcome measure: mI/Cr Outcome measure: NAA/mI
Estimate (SE) p Value Estimate (SE) p Value
Model 1: Estimated rate of change in MRSmetabolites as a function of
baseline Aβ status in the entire cohort
Intercept 0.96 (0.08) <0.001 1.43 (0.20) <0.001
Aβ 0.02 (0.02) 0.18 −0.04 (0.04) 0.29
Visit 2 −0.01 (0.01) 0.21 0.07 (0.37) 0.001
Visit 3 0.02 (0.01) 0.24 0.05 (0.02) 0.15
Age −0.00 (0.00) 0.09 0.00 (0.00) 0.20
APOE 0.02 (0.01) 0.16 −0.07 (0.03) 0.045
Sex −0.03 (0.01) <0.01 −0.07 (0.33) 0.05
Aβ × visit 2 0.05 (0.01) <0.001 −0.16 (0.03) <0.001
Aβ × visit 3 0.04 (0.02) <0.05 −0.16 (0.05) <0.01
Model 2: Estimated rate of change in MRSmetabolites as a function of
baseline diagnoses in the entire cohort
Intercept 0.88 (0.08) <0.001 1.61 (0.21) <0.001
Visit 2 −0.01 (0.01) 0.52 0.04 (0.02) 0.09
Visit 3 −0.01 (0.02) 0.69 0.08 (0.05) 0.11
SCD 0.01 (0.02) 0.70 −0.02 (0.04) 0.61
MCI 0.02 (0.02) 0.35 −0.07 (0.04) 0.13
Age −0.00 (0.00) 0.45 0.00 (0.00) 0.68
APOE 0.04 (0.01) <0.01 −0.11 (0.03) <0.001
Sex −0.03 (0.01) <0.01 0.05 (0.03) 0.08
SCD × visit 2 0.01 (0.02) 0.71 −0.00 (0.04) 0.91
SCD × visit 3 0.03 (0.03) 0.18 −0.07 (0.07) 0.30
MCI × visit 2 0.05 (0.02) <0.01 −0.12 (0.04) <0.01
MCI × visit 3 0.09 (0.03) <0.01 −0.20 (0.07) <0.01
Model 3: Estimated rate of change in MRSmetabolites as a function of
baseline Aβ status in the MCI group
Intercept 1.00 (0.18) <0.001 1.73 (0.40) <0.001
Aβ 0.05 (0.03) 0.19 −0.04 (0.08) 0.56
Visit 2 0.02 (0.02) 0.30 0.01 (0.04) 0.72
Visit 3 0.03 (0.03) 0.33 0.09 (0.06) 0.16
Age −0.00 (0.00) 0.31 −0.00 (0.01) 0.82
APOE 0.01 (0.31) 0.68 −0.05 (0.68) 0.49
Sex −0.03 (0.03) 0.20 0.03 (0.06) 0.59
Aβ × visit 2 0.04 (0.02) 0.07 −0.15 (0.05) <0.01
Aβ × visit 3 0.07 (0.04) 0.06 −0.31 (0.08) <0.001
Abbreviations: Aβ = β-amyloid; Cr = creatine; MCI = mild cognitive impairment; mI = myo-inositol; MRS = magnetic resonance spectroscopy; NAA = N-
acetylaspartate; SCD = subjective cognitive decline.
Baseline levels of factor variables in themodels: Aβ = normal; visit number = visit 1; sex =male; APOE = e4 noncarrier. The primary predictors of interest were
the interaction terms Aβ × visit for model 1 and model 3, and diagnosis × visit for model 2.
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depending on the subjects’ baseline Aβ status (ﬁgure 2, A and
B; table 3). In the Aβ+ group, mI/Cr increased signiﬁcantly
with time at an estimated rate of 1.9%/y, whereas in the Aβ−
group, the increase was minimal at 0.05%/y. The change in the
composite ratio NAA/mI also followed signiﬁcantly diﬀerent
trajectories over time depending on the baseline Aβ status.
Figure 2 Estimated rates of change in mI measures across different biomarker and diagnostic groups
Estimated rates of change inmI/Cr andNAA/mI in different biomarker and diagnostic groups. Model 1 was created using data from the entire cohort to assess whether
baseline Aβ status affects the rate of change in (A) mI/Cr and (B) NAA/mI. Model 2 was built using data from the entire cohort, in order to examine whether baseline
diagnosisaffects therateofchange in (C)mI/Crand (D)NAA/mI.Model3onlyuseddata fromtheMCIgroupas input,examining therateof change in (E)mI/Crand (F)NAA/
mI. Based on these models, we present estimated trajectories of change over time in (G) mI/Cr and (H) NAA/mI for a 71-year-old man, who is an APOE e4 carrier. Aβ =
β-amyloid;Cr= creatine;CTL= cognitivelynormal control;MCI=mild cognitive impairment;mI=myo-inositol;NAA=N-acetylaspartate; SCD= subjectivecognitivedecline.
e400 Neurology | Volume 92, Number 5 | January 29, 2019 Neurology.org/N
NAA/mI declined with the rate of 2.0%/y in the Aβ+ group.
In the Aβ− group, we detected a 1.2% yearly increase in
NAA/mI. However, the increase was only signiﬁcant be-
tween visits 1 and 2.
Model 2 was built using data from the entire cohort, in order
to examine whether baseline diagnosis aﬀects the rate of
change in mI/Cr and NAA/mI, accounting for baseline age,
sex, and APOE e4 carriership, irrespective of baseline Aβ
status. Therefore, the primary predictor of interest for model
2 was the interaction between baseline diagnosis and visit
number. The only signiﬁcant change over time was found in
the MCI group—here, mI/Cr increased by an average of
2.3%/y, whereas NAA/mI decreased by 2.0%/y (ﬁgure 2, C
and D; table 3).
To further characterize these changes, we created model 3,
using only data from theMCI group as input. As expected, the
rates of change were highest in the MCI Aβ+ group at 2.93%/
y (p = 0.07) for mI/Cr and −3.55%/y (p < 0.01) for NAA/mI
(ﬁgure 2, E and F; table 3).
For an overview of the diﬀerences in the rates of change in
mI/Cr and NAA/mI, we present the estimated MRS trajec-
tories for a 71-year-old male APOE e4 carrier for the diﬀerent
Aβ groups and diagnoses (ﬁgure 2, G and H).
MRS and cognitive decline
To investigate whether baseline MRS measurements may be
useful for predicting future cognitive decline, we went on to
create a mixed-eﬀects model using data from the entire co-
hort, where serial MMSE data were predicted as a function of
baseline NAA/mI. Thus, the main predictor of interest was the
interaction termbetweenNAA/mI and visit number.We found
that in participants who were Aβ− at baseline, the decline in
MMSE over 4 years was negligible and eﬀectively independent
of the baseline NAA/mI. However, for Aβ+ participants, the
trajectory of cognitive decline diﬀered signiﬁcantly depending
on baseline NAA/mI (p < 0.01) (ﬁgure 3).
Individuals who were Aβ+ and had low NAA/mI at baseline
(<1.5) declined by a total of 6.3 MMSE points (3.1 points
between visits 1 and 2, and 3.2 points between visits 2 and 3).
Individuals, who were Aβ+ at baseline, yet had higher baseline
NAA/mI (≥1.5), lost a total of 2.2 MMSE points (0.6 be-
tween visits 1 and 2, and 1.6 between visits 2 and 3).
The low-NAA/mI group comprised 25 healthy controls, 22
individuals with SCD, and 22 individuals with MCI. The high-
NAA/mI group comprised 6 controls, 6 SCD, and 19 MCI.
The relationship between baseline MRS and longitudinal
cognition was not signiﬁcant when the diagnostic groups were
analyzed separately.
Furthermore, we investigated whether the absolute change in
NAA/mI during the time between baseline and the last visit
was associated with the absolute change in MMSE during this
time. We found a signiﬁcant positive association between
DNAA/mI andDMMSE in the Aβ+ group but not in the Aβ−
group. In a linear regression model (built using data from the
Aβ+ group), where DNAA/mI was used to estimate the out-
come DMMSE, accounting for sex, age, APOE, and education
level, the variable DNAA/mI was found to be the only signif-
icant predictor of the DMMSE (p < 0.05). The association
Figure 3 Baseline NAA/mI and cognitive decline over time
Cognitive decline as a function of baseline NAA/mI. Serial
MMSE data were predicted as a function of baseline NAA/mI
values. We found a negligible decline in MMSE score for par-
ticipants who were Aβ− at baseline. For Aβ+ participants, the
trajectory of the decline in MMSE score differed significantly
depending on baseline NAA/mI. Aβ+ individuals with low
baseline NAA/mI (<1.5) declined by a total of 6.3 MMSE points.
CSF Aβ+ individuals with high NAA/mI (≥1.5) lost a total of 2.2
MMSE points. Aβ = β-amyloid; mI = myo-inositol; MMSE = Mini-
Mental State Examination; NAA = N-acetylaspartate.
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between DNAA/mI and DMMSE is presented in ﬁgure 4: in
the Aβ+ group, a larger decline in MMSE is associated with
a greater negative change (i.e., greater decline) in NAA/mI.
Discussion
The current study highlights the link between longitudinal
changes in MRS metabolites and the main pathologic hall-
mark of AD—amyloid accumulation. A total of 670 individual
high-quality spectra were analyzed for this study—a number
that far surpasses previous 3-tesla MRS study sample sizes. In
general, few studies have assessed serial MRS measurements
in the context of AD,3,15–17 of which only 2 included patients
with MCI16,17 and none have reported information regarding
amyloid pathology. Based on longitudinal MRS data from
a diagnostically well-characterized cohort of 294 participants
including controls and individuals with SCD and MCI, our
study provides evidence of mI/Cr and NAA/mI being po-
tentially useful markers of Aβ-related pathology. Longitudinal
spectroscopic changes were evaluated in the PCC/precuneus.
This region is highly involved throughout the progression of
AD pathology18–20 and has recently been demonstrated as the
earliest site for amyloid accumulation.21
The association between increased amyloid deposition and
elevated levels of mI has previously been described cross-
sectionally in vivo,4,8 in human tissue,22 and murine models.23
A recent study also demonstrated that higher baseline levels of
mI are associated with an increased rate of Aβ accumulation
over time in cognitively healthy individuals.5 In the present
longitudinal MRS study, we expand on these ﬁndings by
demonstrating that abnormal Aβ levels at baseline are pre-
dictive of elevated mI/Cr and NAA/mI concentrations over
time, and examine this relationship in diﬀerent clinical di-
agnoses. One previous multiple time-point MRS study reports
that only the change in the combined ratio NAA/mI was sig-
niﬁcantly diﬀerent between controls and patients with AD. The
authors reported a 3.7% yearly decline of NAA/mI in patients
with AD and eﬀectively no change in controls.24 Although our
study did not include patients with a baseline AD diagnosis, we
found a similar value for the annualized change in NAA/mI in
the Aβ+ MCI group (3.6% yearly decline), which is coherent
with this group being most similar to the AD patient group. A
2 time-point study that included patients with MCI (but did
not report NAA/mI values) found a 2.6% annual mI/Cr in-
crease for patients with MCI subsequently converting to AD
and 0% for MCI with stable cognitive function. We found
a similar rate of change in theMCI group (2.3%/y). In the Aβ+
MCI group, the composite ratio NAA/mI yielded a yearly
decline of 3.55%, which is comparable to the reported rates of
hippocampal atrophy in MCI.25 Therefore, the ratio NAA/mI
may be useful for monitoring disease progression, also because
working with this composite marker eliminates the need for
internal referencing.
The signal provided by MRS cannot explicitly determine the
type of cell from which the detected resonance originates.
However, since NAA is known to be synthesized exclusively
in the neuronal mitochondria, there is some consensus with
regard to NAA being a suitable marker of neuronal integrity
and mitochondrial function.26,27 There is also evidence of
NAA recovery as cerebral energy balance is restored in trau-
matic brain injury.28 This sensitivity to transient neuronal
dysfunction probably limits the usefulness of NAA alone or
NAA/Cr as a biomarker in AD. The distribution of mI among
diﬀerent cell types in the brain is less well understood. Gen-
erally, glial cells seem to contain higher concentrations of
mI,29,30 but some neuronal cell lines have also been shown to
contain high mI levels.31 Although brain mI levels are elevated
in a number of conditions associated with gliosis, mI can also
increase in absence of glial activation.32 One of the most im-
portant ﬁndings of the current study is the substantial diﬀer-
ence observed in the rate of mI increase between the Aβ− and
Aβ+ groups. Several mechanisms (independent or interlinked)
may be responsible for this phenomenon. A known physiologic
role of mI is that of an organic osmolyte33; intracellular mI
concentrations increase as a response to extracellular hyper-
tonicity34 and decrease in hypotonic conditions.35 Thus, it is
possible that the longitudinal accumulation of mI in the Aβ+
detects osmoregulation—an eﬀort to resist homeostatic aber-
rations associated with pathology. A recent study demonstrated
that mI accumulation in response to hypertonic stress is able to
disturb electrical properties of excitable cells,36 suggesting that
increase in mI observed in our study may be linked to synaptic
dysfunction independently of Aβ. However, there is con-
vincing evidence of a relationship between Aβ plaque pa-
thology and mI. Brain mI is elevated at predementia stages of
Figure 4 Absolute change in NAA/mI and MMSE over 4
years
A larger decline in MMSE score is associated with a greater negative change
(decline) in NAA/mI in Aβ+ participants but not in Aβ− participants. Aβ =
β-amyloid;mI =myo-inositol; MMSE =Mini-Mental State Examination; NAA =
N-acetylaspartate.
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Down syndrome37 and familial AD,38 and antemortem mI
levels are associated with postmortem cored and diﬀuse am-
yloid plaques.23 Furthermore, removal of Aβ plaques attenu-
ates mI levels in APP-PS1 mice.39 A recent retrospective,
longitudinal MRS study found that individuals who had pro-
gressed to AD at 7-year follow-up already had higher mI/Cr
levels at baseline than those who had remained stable.40 It is
therefore probable that the increase in mI/Cr in the Aβ+
group observed in this study is indicative of the ongoing ac-
cumulation of cortical Aβ burden within this group. A serial
amyloid PET study performed in conjunction with serial MRS
would conﬁrm this hypothesis.
It has been shown that individuals with high baseline load of
Aβ are at risk of a steeper cognitive decline.41 Also, there is
recent evidence suggesting that MRS measurements have
the potential to identify individuals at risk of a more rapidly
progressing AD pathology.5 This evidence of an interplay
between MRS concentrations, amyloid accumulation, and
cognition led us to explore the potential of baseline mI/NAA
to predict the trajectory of future cognitive decline. Our
results demonstrate that in the entire sample, Aβ+ individ-
uals with low baseline NAA/mI display a steeper cognitive
decline trajectory, losing on average 4 more MMSE points in
total than those with higher baseline NAA/mI levels. Of
interest, this apparent ability of MRS metabolites to predict
the extent of future decline was only evident in the subgroup
of individuals who were Aβ+ at baseline. We demonstrate
that additional diﬀerentiation of Aβ+ individuals based on an
MRS threshold may reveal subgroups with markedly diﬀerent
rates of cognitive decline over time. The composite ratio NAA/
mI has previously been demonstrated to be a good predictor of
an AD diagnosis.16,40 Our ﬁnding expands on this knowledge
by demonstrating that NAA/mI may be useful for predicting
the extent of cognitive changes (one aspect of disease severity)
at an earlier disease stage. The composite ratio of NAA and
mI in AD is emerging as the most useful MRS marker in AD
since this measure may incorporate 2 of the main disease
hallmarks—amyloid pathology and neurodegeneration.
Although our ﬁndings support the assumption of the existence
of an AD-speciﬁc MRS metabolic signature, it is important to
recognize that this study does not aim to evaluate the usefulness
of MRS as a marker of Aβ positivity, nor does it assess the
ability of MRS alone to predict cognitive decline in the general
population. Rather, we highlight the value in combining CSF
and MRS data and demonstrate that MRS may provide new
information regarding the rate of future cognitive decline once
amyloid positivity has been established. The nature of our study
population is such that the existence of comorbidities cannot
be ruled out. It is therefore possible that some of the alterations
in the MRS proﬁle may be due to other causes. Although
abnormal CSF amyloid measures provide a good indication of
ongoing AD pathology, in an ideal setting, information about
the timing and the number of individuals who convert to AD
should also be used. Furthermore, the lack of normative
spectroscopic data, or a clear understanding of the biological
processes causing MRS alterations, corroborate the need for
CSF measures in order to interpret any MRS changes.
The design of our study was such that a cutoﬀ value has been
used to stratify participants into Aβ− and Aβ+ based on base-
line CSF Aβ42 levels. Furthermore, one of our results suggests
that there may exist some cutoﬀ value for NAA/mI that is
relevant for predicting a worsening of cognitive symptoms.
There are certain disadvantages to working with dichotomized
biomarkers, such as the possible masking of subthreshold
eﬀects and the assessment of individuals close to the cut point.
Nevertheless, applying a normal/abnormal biomarker classiﬁ-
cation is an approach that, apart from being practical, is es-
sential for determining eligibility for clinical trials.42 However,
we recognize that a putative cutoﬀ value for NAA/mI, which
may have relevance for determining an individual’s cognitive
decline proﬁle, must be scrutinized by future studies and vali-
dated in even larger longitudinal cohorts.
The inclusion criteria of the BioFINDER cohort and the ﬁnal
constellation of our study sample may limit the generalizability
of the results of this study. The potential sources of selection
bias in the recruitment of the participants to the BioFINDER
may stem from the relatively high cognitive scores at entry and
the requirement to undergo a lumbar puncture and an MRI.
However, although study participants might be healthier than
the general population, it is unclear in which direction this
would aﬀect the associations found in this study.
In conclusion, our ﬁndings demonstrate that the longitudinal
changes in mI/Cr and NAA/mI are largely governed by the
presence of underlying amyloid pathology, warranting their
potential usefulness as noninvasive dynamic disease biomarkers
during the predementia stages of AD. Today, amyloid and
tau deposition can be imaged using PET, allowing us to assess
molecular pathology in vivo. However, the need remains for
a more widely available cost-eﬀective technique that can be
used for screening dementia and monitoring disease pro-
gression and treatment eﬀects in a clinical setting. Large-scale
multimodal studies that include MRS will help further locate
spectroscopic changes in the continuum of AD pathophysio-
logic processes.
Acknowledgment
The authors thank the collaborators of this study and the
Swedish BioFINDER Study Group.
Study funding
Work at the authors’ research centers was supported by the
European Research Council, the Swedish Research Council,
the Marianne and Marcus Wallenberg Foundation, the Stra-
tegic Research Area MultiPark (Multidisciplinary Research in
Parkinson’s Disease) at Lund University, the Swedish Brain
Foundation, The Kockska Foundation, the Bundy Academy,
The Swedish Alzheimer Foundation, the Skåne University
Hospital Foundation, the Swedish Alzheimer Association, and
the Swedish federal government under the ALF agreement,
Neurology.org/N Neurology | Volume 92, Number 5 | January 29, 2019 e403
Swedish Brain Power, the Strategic Research Programme
in Neuroscience at Karolinska Institutet (StratNeuro), the
Swedish Foundation for Strategic Research (SSF), the regional
agreement on medical training and clinical research (ALF)
between Stockholm County Council and Karolinska Institutet,
the Åke Wiberg Foundation, and the foundation Olle Engkvist
Byggma¨stare. The authors also thank Birgitta och Sten West-
erberg for additional ﬁnancial support.
Disclosure
O. Voevodskaya, K. Poulakis, P. Sundgren, D. van Westen,
S. Palmqvist, L.Wahlund, E. Stomrud, andE.Westman report no
disclosures relevant to the manuscript. O. Hansson has acquired
research support (for the institution) from Roche, GE Health-
care, Biogen, AVID Radiopharmaceuticals, Fujirebio, and
EUROIMMUN. In the past 2 years, he has received consultancy/
speaker fees (paid to the institution) from Lilly, Roche, and
Fujirebio. Go to Neurology.org/N for full disclosures.
Publication history
Received by Neurology March 12, 2018. Accepted in ﬁnal form
September 18, 2018.
References
1. Palmqvist S, Mattsson N, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.
Cerebrospinal ﬂuid analysis detects cerebral amyloid-β accumulation earlier than
positron emission tomography. Brain 2016;139:1226–1236.
2. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in
dominantly inherited Alzheimer’s disease. N Engl J Med 2012;367:795–804.
3. Schott J, Bartlett J, Fox N, Barnes J; Alzheimer’s Disease Neuroimaging Initiative
Investigators. Increased brain atrophy rates in cognitively normal older adults with
low cerebrospinal ﬂuid Aβ1–42. Ann Neurol 2010;68:825–834.
4. Voevodskaya O, Sundgren PC, Strandberg O, et al. Myo-inositol changes precede
amyloid pathology and relate to APOE genotype in Alzheimer disease. Neurology
2016;86:1754–1761.
5. Nedelska Z, Przybelski SA, LesnickTG, et al. 1H-MRSmetabolites and rate of β-amyloid
accumulation on serial PET in clinically normal adults. Neurology 2017;89:1391–1399.
6. O¨z G, Alger JR, Barker PB, et al. Clinical proton MR spectroscopy in central nervous
system disorders. Radiology 2014;270:658–679.
7. Gomar JJ, Gordon ML, Dickinson D, et al. APOE genotype modulates proton
magnetic resonance spectroscopy metabolites in the aging brain. Biol Psychiatry
2013;75:686–692.
8. Kantarci K, Lowe V, Przybelski SA, et al. Magnetic resonance spectroscopy, β-amyloid
load, and cognition in a population-based sample of cognitively normal older adults.
Neurology 2011;77:951–958.
9. Valenzuela M, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001;
56:592–598.
10. Provencher SW. Estimation of metabolite concentrations from localized in vivo
proton NMR spectra. Magn Reson Med 1993;30:672–679.
11. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel.
NMR Biomed 2001;14:260–264.
12. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal ﬂuid and plasma
biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131–144.
13. Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in
clinical practice using cerebrospinal ﬂuid beta-amyloid 42: a cross-validation study
against amyloid positron emission tomography. JAMA Neurol 2014;71:1282–1289.
14. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of proteins in normal
and Alzheimer’s disease cerebrospinal ﬂuid with a sensitive sandwich enzyme-linked
immunosorbent assay. J Neurochem 1993;61:1828–1834.
15. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD. Longitudinal quantitative
proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease.
Brain 2002;125:2332–2341.
16. Kantarci K, Weigand SD, Petersen RC, et al. Longitudinal 1H MRS changes in mild
cognitive impairment and Alzheimer’s disease. Neurobiol Aging 2007;28:1330–1339.
17. Modrego PJ, Fayed N, Sarasa M. Magnetic resonance spectroscopy in the prediction
of early conversion from amnestic mild cognitive impairment to dementia: a pro-
spective cohort study. BMJ Open 2011;1:e000007.
18. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta
Neuropathol 1991;82:239–259.
19. Lehmann M, Rohrer JD, Clarkson MJ, et al. Reduced cortical thickness in the pos-
terior cingulate gyrus is characteristic of both typical and atypical Alzheimer’s disease.
J Alzheimers Dis 2010;20:587–598.
20. Minoshima S, Giordani B, Berent S, Frey K, Foster N, Kuhl D. Metabolic reduction
in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol
1997;42:85–94.
21. Palmqvist S, Scho¨ll M, Strandberg O, et al. Earliest accumulation of β-amyloid occurs
within the default-mode network and concurrently aﬀects brain connectivity. Nat
Commun 2017;8:1214.
22. Kantarci K, Knopman DS, Dickson DW, et al. Alzheimer disease: postmortem neu-
ropathologic correlates of antemortem 1H MR spectroscopy metabolite measure-
ments. Radiology 2008;248:210–220.
23. Murray ME, Przybelski SA, Lesnick TG, et al. Early Alzheimer’s disease neuropa-
thology detected by proton MR spectroscopy. J Neurosci 2014;34:16247–16255.
24. Schott JM, Frost C, MacManus DG, Ibrahim F, Waldman AD, Fox NC. Short echo
time proton magnetic resonance spectroscopy in Alzheimer’s disease: a longitudinal
multiple time point study. Brain 2010;133:3315–3322.
25. Henneman WJ, Sluimer JD, Barnes J, et al. Hippocampal atrophy rates in Alzheimer
disease: added value over whole brain volume measures. Neurology 2009;72:999–1007.
26. Dautry C, Françoise V, Emmanuel B, et al. Early N-acetylaspartate depletion is a marker
of neuronal dysfunction in rats and primates chronically treated with the mitochondrial
toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 2000;20:789–799.
27. Moﬀett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AMA. N-acetylaspartate in
the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007;81:89–131.
28. Signoretti S, Marmarou A, Aygok GA, Fatouros PP, Portella G, Bullock RM. As-
sessment of mitochondrial impairment in traumatic brain injury using high-resolution
proton magnetic resonance spectroscopy. J Neurosurg 2008;108:42–52.
29. Glanville NT, Byers DM, Cook HW, Spence MW, Palmer FB. Diﬀerences in the
metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial
origin. Biochim Biophys Acta 1989;1004:169–179.
30. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy
metabolism of glial and neuronal cells. Dev Neurosci 1993;15:289–298.
31. Fisher S, Novak J, Agranoﬀ B. Inositol and higher inositol phosphates in neural
tissues: homeostasis, metabolism and functional signiﬁcance. J Neurochem 2002;
82:736–754.
32. Bartha R, SmithM, Rupsingh R, Rylett J, Wells JL, Borrie MJ. High ﬁeld (1)HMRS of
the hippocampus after donepezil treatment in Alzheimer disease. Prog Neuro-
psychopharmacol Biol Psychiatry 2008;32:786–793.
33. Kwon HM, Yamauchi A, Uchida S, et al. Cloning of the cDNa for a Na+/myo-inositol
cotransporter, a hypertonicity stress protein. J Biol Chem 1992;267:6297–6301.
34. Lee JH, Arcinue E, Ross BD. Organic osmolytes in the brain of an infant with
hypernatremia. N Engl J Med 1994;331:439–442.
35. Videen JS, Michaelis T, Pinto P, Ross BD. Human cerebral osmolytes during chronic
hyponatremia: a proton magnetic resonance spectroscopy study. J Clin Invest 1995;
95:788–793.
36. Dai G, Yu H, Kruse M, Traynor-Kaplan A, Hille B. Osmoregulatory inositol trans-
porter SMIT1 modulates electrical activity by adjusting PI(4,5)P2 levels. Proc Natl
Acad Sci USA 2016;113:E3290–E3299.
37. Huang W, Alexander GE, Daly EM, et al. High brain myo-inositol levels in the
predementia phase of Alzheimer’s disease in adults with Down’s syndrome: a 1HMRS
study. Am J Psychiatry 1999;156:1879–1886.
38. Godbolt AK, Waldman AD, MacManus DG, et al. MRS shows abnormalities before
symptoms in familial Alzheimer disease. Neurology 2006;66:718–722.
39. Marjan´ska M,Weigand SD, Preboske G, et al. Treatment eﬀects in a transgenic mouse
model of Alzheimer’s disease: a magnetic resonance spectroscopy study after passive
immunization. Neuroscience 2014;259:94–100.
40. Waragai M, Moriya M, Nojo T. Decreased N-acetyl aspartate/myo-inositol ratio in
the posterior cingulate cortex shown by magnetic resonance spectroscopy may be one
of the risk markers of preclinical Alzheimer’s disease: a 7-year follow-up study.
J Alzheimers Dis 2017;60:1411–1427.
41. Donohue MC, Sperling RA, Petersen R, et al. Association between elevated brain
amyloid and subsequent cognitive decline among cognitively normal persons. JAMA
2017;317:2305–2316.
42. Jack CR Jr, Wiste HJ, Weigand SD, et al. Deﬁning imaging biomarker cut points for
brain aging and Alzheimer’s disease. Alzheimers Dement 2017;13:205–216.
e404 Neurology | Volume 92, Number 5 | January 29, 2019 Neurology.org/N
Appendix 1 Authors contribution




Division of Clinical Geriatrics, Department of Neurobiology, Care
Sciences and Society, Karolinska Institute, Stockholm, Sweden
Author Study design and concept, analysis and




Division of Clinical Geriatrics, Department of Neurobiology, Care
Sciences and Society, Karolinska Institute, Stockholm, Sweden




Department of Diagnostic Radiology, Lund University, Sweden Author Acquisition and interpretation of data, critical





Department of Diagnostic Radiology, Lund University; and Imaging and
Function, Skåne University Health Care, Lund, Sweden
Author Acquisition and interpretation of data, critical





Clinical Memory Research Unit, Department of Clinical Sciences, Malmo¨,
Lund University, Sweden
Author Acquisition and interpretation of data, critical





Division of Clinical Geriatrics, Department of Neurobiology, Care
Sciences and Society, Karolinska Institute, Stockholm, Sweden
Author Interpretation of data, critical revision of the
manuscript for important intellectual content
Erik Stomrud,
MD, PhD
Clinical Memory Research Unit, Department of Clinical Sciences, Malmo¨,
Lund University; and Memory Clinic, Skåne University Hospital, Malmo¨,
Sweden
Author Acquisition and interpretation of data, critical





Clinical Memory Research Unit, Department of Clinical Sciences, Malmo¨,
Lund University; and Memory Clinic, Skåne University Hospital, Malmo¨,
Sweden




Division of Clinical Geriatrics, Department of Neurobiology, Care
Sciences and Society, Karolinska Institute, Stockholm, Sweden; and
Department of Neuroimaging, Centre for Neuroimaging Sciences,
Institute of Psychiatry, Psychology and Neuroscience, King’s College
London, UK
Author Study design and concept, drafting the
manuscript, study supervision
Appendix 2 Coinvestigators
Name Location Role Contribution
Kaj Blennow, MD,
PhD












Responsible for the analysis of CSF
biomarkers
Neurology.org/N Neurology | Volume 92, Number 5 | January 29, 2019 e405
DOI 10.1212/WNL.0000000000006852
2019;92;e395-e405 Published Online before print January 4, 2019Neurology 
Olga Voevodskaya, Konstantinos Poulakis, Pia Sundgren, et al. 
study
Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal




including high resolution figures, can be found at:
References
 http://n.neurology.org/content/92/5/e395.full#ref-list-1
This article cites 42 articles, 10 of which you can access for free at: 
Citations
 http://n.neurology.org/content/92/5/e395.full##otherarticles













its entirety can be found online at:




Information about ordering reprints can be found online:
ISSN: 0028-3878. Online ISSN: 1526-632X.
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Print
1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2019 The Author(s). Published by 
® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology 
